Scarica l'app Stockscreener
2.72
1.49%
0.04
Dopo l'orario di chiusura:
2.76
0.04
+1.47%
Precedente Chiudi:
$2.68
Aprire:
$2.68
Volume 24 ore:
345.25K
Relative Volume:
0.41
Capitalizzazione di mercato:
$196.42M
Reddito:
-
Utile/perdita netta:
$-121.34M
Rapporto P/E:
-1.3576
EPS:
-2.0035
Flusso di cassa netto:
$-115.63M
1 W Prestazione:
+5.43%
1M Prestazione:
-16.82%
6M Prestazione:
+19.30%
1 anno Prestazione:
+159.05%
Intervallo 1D:
$2.635
$2.74
Intervallo di 1 settimana:
$2.45
$2.74
Portata 52W:
$0.8551
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Nome
Acumen Pharmaceuticals Inc
Settore
Industria
Telefono
617-344-4190
Indirizzo
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.72 | 193.53M | 0 | -121.34M | -115.63M | -2.0035 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-07-26 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-20 | Ripresa | BofA Securities | Buy |
| 2023-05-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Iniziato | BTIG Research | Buy |
| 2022-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-07-26 | Iniziato | BofA Securities | Neutral |
| 2021-07-26 | Iniziato | Credit Suisse | Outperform |
| 2021-07-26 | Iniziato | Stifel | Buy |
| 2021-07-26 | Iniziato | UBS | Buy |
Mostra tutto
Acumen Pharmaceuticals Inc Borsa (ABOS) Ultime notizie
Aug Selloffs: Is Acumen Pharmaceuticals Inc a strong candidate for buy and hold2026 Chart Watch & Safe Capital Allocation Plans - baoquankhu1.vn
Chart Watch: What is the earnings history of Acumen Pharmaceuticals IncMarket Risk Report & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Aug Chart Watch: What is the earnings history of Acumen Pharmaceuticals IncGDP Growth & Short-Term High Return Strategies - baoquankhu1.vn
ABOS Forecast, Price Target & Analyst Ratings | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
James B. Murray Jr. discloses 3.61M shares in Acumen Pharmaceuticals (NASDAQ: ABOS) - Stock Titan
ABOS Technical Analysis & Stock Price Forecast - Intellectia AI
Meme Stocks: Is Acumen Pharmaceuticals Inc being accumulated by smart moneyPortfolio Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
ABOS Technical Analysis | Trend, Signals & Chart Patterns | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
Acumen Pharmaceuticals’ Earnings Call: Promise Amid Pressure - TipRanks
Acumen Pharmaceuticals (ABOS) loses 33.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q4 2025 Earnings Conference - 富途牛牛
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2025 Earnings Call Transcript - Insider Monkey
[EFFECT] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan
Acumen Pharmaceuticals (NASDAQ: ABOS) registers 10.83M resale shares - Stock Titan
Is Acumen Pharmaceuticals (ABOS) stock outpacing its medical peers this year? - MSN
ABOS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding - MSN
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - finance.yahoo.com
Aug Final Week: Can Acumen Pharmaceuticals Inc reach resistance levels soon - baoquankhu1.vn
Acumen Pharmaceuticals (ABOS) Drops 33.6% Over the Past Month, Reasons Suggest a Potential Turnaround Could Be Imminent - Bitget
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Should I buy Acumen Pharmaceuticals (ABOS) - Zacks Investment Research
Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Increased to Hold at Wall Street Zen - MarketBeat
Acumen Pharmaceuticals files to sell 10.83M shares of common stock for holders - MSN
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - finance.yahoo.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Acumen Pharmaceuticals Reports 2025 Financial Results and Advances Alzheimer’s Drug Pipeline with Phase 2 ALTITUDE-AD Study and Enhanced Brain Delivery Program - Minichart
10.8M Acumen shares registered for resale (NASDAQ: ABOS) - stocktitan.net
Acumen Pharmaceuticals Inc (ABOS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Acumen Pharmaceuticals (NASDAQ: ABOS) details sabirnetug Alzheimer’s program and funding risks - Stock Titan
Acumen Updates Alzheimer’s Pipeline, Extends Cash Runway Into 2027 - TipRanks
Stifel reiterates Acumen Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Stifel reiterates Acumen Pharmaceuticals stock rating at buy - Investing.com
Acumen Pharmaceuticals 2025 Financial Review - AlphaStreet
Acumen Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Acumen Pharmaceuticals (NASDAQ:ABOS) Receives "Buy" Rating from BTIG Research - MarketBeat
Acumen Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
ABOS: ALTITUDE-AD phase II and EBD advances drive robust pipeline and financial momentum - TradingView — Track All Markets
Acumen Pharmaceuticals (NASDAQ:ABOS) Announces Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Earnings call transcript: Acumen Pharmaceuticals Q4 2025 reveals strategic advancements By Investing.com - Investing.com South Africa
Earnings call transcript: Acumen Pharmaceuticals Q4 2025 reveals strategic advancements - Investing.com Canada
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
ABOS: ALTITUDE-AD trial advances, EBD pipeline expands, and $35.75M raised for Alzheimer's innovation - TradingView
Cantor Fitzgerald reiterates Acumen Pharmaceuticals stock rating By Investing.com - Investing.com India
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Narrower-Than-Expected Q4 Loss, Provides Key Clinical Update - ChartMill
Patterns Watch: What is the earnings history of Acumen Pharmaceuticals IncSell Signal & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Cantor Fitzgerald reiterates Acumen Pharmaceuticals stock rating - investing.com
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights - Bitget
ACUMEN PHARMACEUTICALS ($ABOS) Releases Q4 2025 Earnings - Quiver Quantitative
Acumen Pharmaceuticals Inc Azioni (ABOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):